A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Fred Hutchinson Cancer Center
Stanford University
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Incyte Corporation
Prelude Therapeutics
City of Hope Medical Center
Incyte Corporation
M.D. Anderson Cancer Center
Mayo Clinic
Washington University School of Medicine
Dana-Farber Cancer Institute